top of page

Indian Pharma News | 2024 | iPharmaCenter

May 21, 2024

Glenmark and BeiGene Collaborate to Market and Distribute Tislelizumab and Zanubrutinib in India

Key Points:

  • Tislelizumab: An innovative anti-PD-1 monoclonal antibody approved by NMPA, EMA, and FDA for treating advanced or metastatic esophageal squamous cell carcinoma and other cancers.

  • Zanubrutinib: A BTK inhibitor approved for treating specific hematological cancers, showing strong efficacy and safety in various studies.

  • Agreement Scope: Glenmark will handle the local development, registration, and distribution of these oncology medicines, expanding access for cancer patients across India.

Glenmark Specialty announced an exclusive marketing and distribution partnership with BeiGene, a worldwide oncology company. According to this agreement, Glenmark will register and commercialize BeiGene's cancer therapies, tislelizumab and zanubrutinib, in India.

Statistics reveal that India ranks third globally in cancer cases, with projections indicating the number could rise to 2.08 million by 2040—a 57.5% increase from 2020. Currently, cancer causes approximately 900,000 deaths annually in India.

While most cancer diagnoses are solid tumors, there is a significant rise in blood cancers, with India ranking third globally after the US and China. In India, a blood cancer diagnosis occurs every five minutes, resulting in an estimated 70,000 deaths each year. Given this alarming situation, Glenmark aims to provide affordable and effective therapies, offering hope to those affected by cancer.


January 08, 2024

Cipla Embarks on Transformative Collaboration for Global Advancement of Cell Therapy Solutions

Cipla Limited has recently announced a significant partnership with Kemwell Biopharma Private Limited and Manipal Education & Medical Group, alongside their respective subsidiaries, Kemwell Biopharma UK Limited and MNI Ventures, Mauritius. This collaborative effort is geared towards establishing a joint venture in the United States, focusing on the global development and commercialization of groundbreaking Cell therapy products designed to address critical medical needs in the United States, Japan, and the EU.

The joint venture will see Cipla (EU) Limited securing a substantial 35.2% stake, strategically leveraging its expertise in product development and commercialization. Teaming up with Kemwell, renowned for its biologics proficiency, and Manipal, known for its excellence in healthcare delivery, this collaboration aims to expedite the progress of cutting-edge Cell therapy solutions across various stages, including development, manufacturing, licensing, and international trade.

This collaboration signifies the second joint venture between Cipla and Kemwell Biopharma, following the establishment of Aspergen Inc., USA in 2022. Aspergen Inc. is actively engaged in the global development, manufacturing, and commercialization of biosimilars, contributing to Cipla's global leadership in lung-related therapies.



bottom of page